References

Early Fluorescence in situ Hybridization Assessment during Acute Myeloid Leukemia Induction Chemotherapy., Schneidewend R,Hosking P,Brazauskas R,Peterson J,Beaudin C,Michaelis L,Atallah E,Hari P,Carlson K,, Acta haematologica, 2018 Mar 29     [PubMed PMID: 29597188]
Atypical Presentation of Acute Myeloid Leukemia., Agrawal K,Miles L,Agrawal N,Khan A,, World journal of oncology, 2018 Feb     [PubMed PMID: 29581813]
Molecular Minimal Residual Disease in Acute Myeloid Leukemia., Jongen-Lavrencic M,Grob T,Hanekamp D,Kavelaars FG,Al Hinai A,Zeilemaker A,Erpelinck-Verschueren CAJ,Gradowska PL,Meijer R,Cloos J,Biemond BJ,Graux C,van Marwijk Kooy M,Manz MG,Pabst T,Passweg JR,Havelange V,Ossenkoppele GJ,Sanders MA,Schuurhuis GJ,Löwenberg B,Valk PJM,, The New England journal of medicine, 2018 Mar 29     [PubMed PMID: 29601269]
Checkpoint inhibitors and acute myelogenous leukemia: promises and challenges., Alfayez M,Borthakur G,, Expert review of hematology, 2018 Mar 28     [PubMed PMID: 29589969]